Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma

Table 1 Laboratory findings in case 1

	BL	Week 1	Week 2	Week 4	Week 8	Week 12 (ETR)	Week 12 post therapy (SVR-12)	Week 24 post therapy (SVR-24)
Hgb (g/L)	106	107	97	85	79	89	105	111
WBC (G/L)	3.2	2.4	3.7	5.8	5.3	3.5	4.5	4.7
PLT (G/L)	80	69	111	123	136	94	81	91
TBil/DBil (μmol/L)	16/10	98/47	66/34	41/25	42/9	13/7	10/5	12/5
ALT (U/L)	49	28	20	23	25	15	11	15
Alb (g/L)	39	39	42	41	36	38	44	44
PT (s)	14.4	14.2	14.9	15.8	14.5	15.1	14.2	15.3
HCV RNA (IU/mL)	496183		UND	UND		UND	UND	UND
FIBROMAXTM	A2/F4					A0/F4
TBA (μmol/L)	27					39	33.5

BL: Treatment baseline; ETR: End of treatment response; SVR-12: Sustained virological response 12 wk post therapy; SVR-24: Sustained virological response 24-wk post therapy; UND: Undetectable; Hgb: Hemoglobin; WBC: White blood cell count; PLT: Platelet count; TBil: Total bilirubin; DBil: Direct bilirubin; ALT: Alanine aminotransferase; Alb: Albumin; PT: Prothrombin time; HCV: Hepatitis C virus; TBA: Total bile acids.